Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil
Rev. Soc. Bras. Med. Trop
; Rev. Soc. Bras. Med. Trop;52: e20180272, 2019. tab, graf
Article
em En
| LILACS
| ID: biblio-1041550
Biblioteca responsável:
BR1.1
ABSTRACT
Abstract INTRODUCTION:
Visceral leishmaniasis (VL) is fatal if not diagnosed and treated. This study aimed to estimate the cost-effectiveness of diagnostic-therapeutic alternatives for VL in Brazil.METHODS:
A decision model estimated the life expectancy and costs of six diagnostic-therapeutic strategies.RESULTS:
IT LEISH + liposomal amphotericin B emerged the best option, presenting lower costs and higher effectiveness. DAT-LPC + liposomal amphotericin B showed an incremental cost-effectiveness ratio of US$ 326.31 per life year.CONCLUSIONS:
These findings indicate the feasibility of incorporating DAT and designating liposomal amphotericin B as the first-line drug for VL in Brazil.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
LILACS
Assunto principal:
Anfotericina B
/
Análise Custo-Benefício
/
Leishmaniose Visceral
/
Meglumina
/
Antiprotozoários
Tipo de estudo:
Diagnostic_studies
/
Health_economic_evaluation
/
Prognostic_studies
Aspecto:
Patient_preference
Limite:
Humans
País/Região como assunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Rev. Soc. Bras. Med. Trop
Assunto da revista:
MEDICINA TROPICAL
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Brasil
País de publicação:
Brasil